Abstract
Sjogren’s syndrome (SS) is a chronic inflammatory disease characterized by salivary and lacrimal gland dysfunction although extraglandular manifestations are also found. Suitable study models and in vitro cell culture designs are used to approach SS pathogenic mechanisms. Cellular and molecular pathways involved in gland homeostasis loss and the autoimmune response are focused in the search of novel drug targets and biomarkers. Vasoactive intestinal peptide (VIP) has trophic, pro-secretory and immunomodulatory effects in several chronic and autoimmune disease models. Here we review evidence pointing to its role as an endogenous modulator of gland homeostasis at early stages of the disease. Particularly, mechanisms involving VIP/VPAC system in the course of salivary function impairment in the non obese diabetic (NOD) mouse model of Sjögren’s syndrome are described.
Keywords: Vasoactive intestinal peptide – Sjogren Syndrome – Salivary epithelial cells.
Current Pharmaceutical Design
Title:Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Volume: 20 Issue: 29
Author(s): Hauk Vanesa, Calafat Mario, Grasso Esteban, Fraccaroli Laura, Paparini Daniel, Ramhorst Rosanna and Perez Leiros Claudia
Affiliation:
Keywords: Vasoactive intestinal peptide – Sjogren Syndrome – Salivary epithelial cells.
Abstract: Sjogren’s syndrome (SS) is a chronic inflammatory disease characterized by salivary and lacrimal gland dysfunction although extraglandular manifestations are also found. Suitable study models and in vitro cell culture designs are used to approach SS pathogenic mechanisms. Cellular and molecular pathways involved in gland homeostasis loss and the autoimmune response are focused in the search of novel drug targets and biomarkers. Vasoactive intestinal peptide (VIP) has trophic, pro-secretory and immunomodulatory effects in several chronic and autoimmune disease models. Here we review evidence pointing to its role as an endogenous modulator of gland homeostasis at early stages of the disease. Particularly, mechanisms involving VIP/VPAC system in the course of salivary function impairment in the non obese diabetic (NOD) mouse model of Sjögren’s syndrome are described.
Export Options
About this article
Cite this article as:
Vanesa Hauk, Mario Calafat, Esteban Grasso, Laura Fraccaroli, Daniel Paparini, Rosanna Ramhorst and Claudia Leiros Perez, Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function, Current Pharmaceutical Design 2014; 20 (29) . https://dx.doi.org/10.2174/1381612820666140130203636
DOI https://dx.doi.org/10.2174/1381612820666140130203636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology The TCR/CD3 Complex: Opening the Gate to Successful Vaccination
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors
Anti-Cancer Agents in Medicinal Chemistry P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design HCV Infection by Cell-to-Cell Transmission: Choice or Necessity?
Current Molecular Medicine From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Molecular Aspects of Modulation of L-type Calcium Channels by Protein Kinase C
Current Molecular Pharmacology Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Bone Metastases Radiopharmaceuticals: An Overview
Current Radiopharmaceuticals Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pharmacology of Cell Adhesion Molecules of the Nervous System
Current Neuropharmacology MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design